Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,otherCurrentAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,dividendsPaid,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ISR,67981000.0,141200000,362000,,-745000,,-745000,1764000,1362000,-764000,-764000,,,,,,0,2600000,3364000,1238000,19000,,-745000,-745000,117000.0,158221000.0,3182000.0,68098000.0,71280000.0,141000.0,-90264000.0,677000.0,374000.0,64841000.0,1916000.0,2715000.0,68074000.0,2019000.0,731000.0,992000.0,,498000.0,-99000.0,55976000.0,-186000.0,55976000.0,55256000.0,-621000.0,52000.0,-7000.0,-56000.0,-281000.0,97000.0,-93000.0,,66158000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.65,1630526400,0.00999999,0.6203,0.6688,0.6203,704072,-21.666666,0.146,0.6702857,-0.020285726,-0.030264298,0.9143478,-0.26434785,-0.2891108,91780000,-21.666666,4.4520545,15,America/New_York,EDT,False,False,USD,-0.03,us_market,"IsoRay, Inc.",ASE,PRE,4,1.5624986,0.6203 - 0.6688,0.64,0.0,0.693,10,18,finmb_9934314,NYSE American,"Isoray, Inc.",USD,933181,853057,0.29999998,0.8571428,0.35 - 2.81,-2.1599998,-0.76868325,0.35,2.81,1620936000,1620936000,0,1620936000,-0.046,-0.03,-14400000,1.05,,,2.81,0.35,0.6703,0.9143,933.18k,853.06k,141.2M,,140.06M,0.77%,12.45%,1.33M,2.14,0.95%,0.94%,1.28M,,,,,,0.00%,,,1:30,"Aug 16, 2005","Jun 29, 2020","Mar 30, 2021",-36.52%,-36.72%,-5.50%,-9.51%,9.62M,0.11,-9.70%,5.12M,-3.33M,-3.52M,-0.0460,,64.84M,0.46,838k,1.23,35.53,0.15,-2.57M,-1.58M,Value,99354,Healthcare,53,"Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.",Richland,509 375 1202,WA,1609372800,United States,http://isoray.com,86400,350 Hills Street,Medical Instruments & Supplies,Suite 106
t-1,ISR,12654000.0,141200000,285000,,-868000,,-868000,1748000,1167000,-866000,-866000,,,,,,0,2359000,3225000,1192000,-2000,,-868000,-868000,119000.0,102205000.0,2740000.0,12773000.0,15513000.0,87000.0,-89519000.0,753000.0,384000.0,9585000.0,1335000.0,2721000.0,12289000.0,1738000.0,665000.0,494000.0,,-264000.0,-60000.0,8465000.0,232000.0,8474000.0,7645000.0,-760000.0,54000.0,-7000.0,-22000.0,20000.0,88000.0,-60000.0,-9000.0,10954000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.65,1630526400,0.00999999,0.6203,0.6688,0.6203,704072,-21.666666,0.146,0.6702857,-0.020285726,-0.030264298,0.9143478,-0.26434785,-0.2891108,91780000,-21.666666,4.4520545,15,America/New_York,EDT,False,False,USD,-0.03,us_market,"IsoRay, Inc.",ASE,PRE,4,1.5624986,0.6203 - 0.6688,0.64,0.0,0.693,10,18,finmb_9934314,NYSE American,"Isoray, Inc.",USD,933181,853057,0.29999998,0.8571428,0.35 - 2.81,-2.1599998,-0.76868325,0.35,2.81,1620936000,1620936000,0,1620936000,-0.046,-0.03,-14400000,1.05,,,2.81,0.35,0.6703,0.9143,933.18k,853.06k,141.2M,,140.06M,0.77%,12.45%,1.33M,2.14,0.95%,0.94%,1.28M,,,,,,0.00%,,,1:30,"Aug 16, 2005","Jun 29, 2020","Mar 30, 2021",-36.52%,-36.72%,-5.50%,-9.51%,9.62M,0.11,-9.70%,5.12M,-3.33M,-3.52M,-0.0460,,64.84M,0.46,838k,1.23,35.53,0.15,-2.57M,-1.58M,Value,99354,Healthcare,53,"Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.",Richland,509 375 1202,WA,1609372800,United States,http://isoray.com,86400,350 Hills Street,Medical Instruments & Supplies,Suite 106
t-2,ISR,4967000.0,141200000,312000,,-713000,,-713000,1648000,1246000,-714000,-714000,,,,,,0,2384000,3098000,1138000,1000,,-713000,-716000,128000.0,93677000.0,2930000.0,5095000.0,8025000.0,69000.0,-88651000.0,693000.0,386000.0,1940000.0,1522000.0,2765000.0,4746000.0,1758000.0,641000.0,758000.0,,106000.0,-113000.0,8465000.0,-91000.0,8474000.0,-451000.0,-338000.0,52000.0,-7000.0,-63000.0,286000.0,85000.0,-113000.0,-9000.0,3224000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.65,1630526400,0.00999999,0.6203,0.6688,0.6203,704072,-21.666666,0.146,0.6702857,-0.020285726,-0.030264298,0.9143478,-0.26434785,-0.2891108,91780000,-21.666666,4.4520545,15,America/New_York,EDT,False,False,USD,-0.03,us_market,"IsoRay, Inc.",ASE,PRE,4,1.5624986,0.6203 - 0.6688,0.64,0.0,0.693,10,18,finmb_9934314,NYSE American,"Isoray, Inc.",USD,933181,853057,0.29999998,0.8571428,0.35 - 2.81,-2.1599998,-0.76868325,0.35,2.81,1620936000,1620936000,0,1620936000,-0.046,-0.03,-14400000,1.05,,,2.81,0.35,0.6703,0.9143,933.18k,853.06k,141.2M,,140.06M,0.77%,12.45%,1.33M,2.14,0.95%,0.94%,1.28M,,,,,,0.00%,,,1:30,"Aug 16, 2005","Jun 29, 2020","Mar 30, 2021",-36.52%,-36.72%,-5.50%,-9.51%,9.62M,0.11,-9.70%,5.12M,-3.33M,-3.52M,-0.0460,,64.84M,0.46,838k,1.23,35.53,0.15,-2.57M,-1.58M,Value,99354,Healthcare,53,"Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.",Richland,509 375 1202,WA,1609372800,United States,http://isoray.com,86400,350 Hills Street,Medical Instruments & Supplies,Suite 106
t-3,ISR,5585000.0,141200000,322000,,-1188000,,-1188000,1938000,1071000,-1189000,-1189000,,,,,,0,2279000,3468000,1208000,1000,,-1188000,-1191000,138000.0,93592000.0,2976000.0,5723000.0,8699000.0,69000.0,-87938000.0,632000.0,318000.0,2392000.0,1575000.0,2736000.0,5507000.0,2075000.0,645000.0,654000.0,27000.0,-287000.0,-39000.0,874000.0,327000.0,874000.0,-13000.0,-848000.0,42000.0,-14000.0,-76000.0,103000.0,223000.0,-25000.0,-9000.0,3932000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.65,1630526400,0.00999999,0.6203,0.6688,0.6203,704072,-21.666666,0.146,0.6702857,-0.020285726,-0.030264298,0.9143478,-0.26434785,-0.2891108,91780000,-21.666666,4.4520545,15,America/New_York,EDT,False,False,USD,-0.03,us_market,"IsoRay, Inc.",ASE,PRE,4,1.5624986,0.6203 - 0.6688,0.64,0.0,0.693,10,18,finmb_9934314,NYSE American,"Isoray, Inc.",USD,933181,853057,0.29999998,0.8571428,0.35 - 2.81,-2.1599998,-0.76868325,0.35,2.81,1620936000,1620936000,0,1620936000,-0.046,-0.03,-14400000,1.05,,,2.81,0.35,0.6703,0.9143,933.18k,853.06k,141.2M,,140.06M,0.77%,12.45%,1.33M,2.14,0.95%,0.94%,1.28M,,,,,,0.00%,,,1:30,"Aug 16, 2005","Jun 29, 2020","Mar 30, 2021",-36.52%,-36.72%,-5.50%,-9.51%,9.62M,0.11,-9.70%,5.12M,-3.33M,-3.52M,-0.0460,,64.84M,0.46,838k,1.23,35.53,0.15,-2.57M,-1.58M,Value,99354,Healthcare,53,"Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.",Richland,509 375 1202,WA,1609372800,United States,http://isoray.com,86400,350 Hills Street,Medical Instruments & Supplies,Suite 106
